The market for Acadia Pharmaceuticals Inc.’s Nuplazid (pimavanserin) could grow to 10 times its current Parkinson’s disease psychosis population if it is approved to treat dementia-related psychosis based on the results of a Phase III study presented on 4 December at the Clinical Trials on Alzheimer’s Disease (CTAD) conference in San Diego.
Acadia stopped the Phase III HARMONY trial early in September based on positive interim efficacy, and in data presented at CTAD the company showed that dementia patients treated with pimavanserin were 2.8 times less likely to have a psychotic relapse than those who received a placebo during the randomized portion of the study. San Diego-based Acadia will submit a supplemental new drug application (sNDA) for pimavanserin in the treatment of dementia-related psychosis (DRP) to the US Food and Drug Administration in 2020 based on these results